ANGPTL3 and ovarian carcinoma: The present study aims to measure and report circulating levels of ANGPTL3, PCSK9 and Apo CIII in women with ovarian carcinoma (OC); all three lipid-modulating factors are the target of clinically available therapeutical monoclonal antibodies or antisense oligonucleotide therapy.